General Information
Merck Vaccine V116
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccina in Adults 50 years of Age or Older.
| Protocol | V116-005-0067 |
|---|---|
| Identifier | |
| UID | 35d75866-8e17-48ba-9819-a6d54f64a862 |
| Status | Done - Archived |
| Phase | 3 |
| Category | Vaccine / Adult |
| Launch Year | 2022 |
| NCT Number | - |
| Created | 2022-05-24 11:27 |
| Last Updated | 2023-09-26 17:45 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2022-11-15 | No |
| Enrollment Open | 2023-10-18 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2022-08-30 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2023-09-13 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Navarrete, Connie | CNavarrete | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Merck Inc. |
|---|---|
| Division | Merck Inc. |
| Team | Merck Inc. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
